我担任澳门在线赌城娱乐晚期肿瘤学研究和开发的全球产品负责人. In my role, 我领导肿瘤化合物的全球开发团队，从3期临床试验开始到上市及以后.

I am most passionate about science and people. 我的职业生涯始于学术界，但在过去的二十年里，我一直专注于澳门在线赌城娱乐的肿瘤研究和开发，因为我一直致力于帮助癌症患者. 我在澳门在线赌城娱乐的工作是我的激情的完美结合——澳门第一赌城在线娱乐有一个非常强大的产品线，以卓越的科学为基础, and we take a truly patient-centric approach.

Over the years, I have held bioscience, 翻译科学和项目领导角色在早期和后期的发展, across AstraZeneca’s oncology franchises, with recent particular focus in breast cancer. 我是发现EGFR+肺癌靶向治疗的团队的早期项目负责人.

我在乳腺癌方面也有重要的专业知识，曾领导团队为澳门在线赌城娱乐和MedImmune的乳腺癌治疗开发制定战略. 我目前正在领导一个晚期肿瘤学的雌激素受体靶向项目，并与人合著了超过35篇同行评审的出版物，其中包括论文 Nature, Clinical Cancer Research, Cancer Discovery and J Cell Science.

Before joining AstraZeneca, 我在曼彻斯特大学获得了细胞生物学和胚胎发育的博士学位，并在一家专注于伤口愈合的初创生物技术公司工作.

 

我热衷于通过为患者带来新药和创新来发挥作用, working collaboratively with industry, academia and the patients themselves.

Teresa Klinowska Global Product Leader, Oncology R&D

Honor

2018年：受邀参加美国食品和药物管理局公共研讨会：优化早期乳腺癌预后的临床试验, Washington DC.

Shortlisted

2019: Shortlisted for AstraZeneca’s R&为中国食品药品监督管理总局/药品审评中心举办培训工作坊获得D奖

Award

2013年：澳门在线赌城娱乐首席执行官“实现科学领导力”奖

Teresa Klinowska

CURRENT ROLE

Global Product Leader, Oncology R&D

2014 – 2019

Led global, cross-functional, oncology project teams from preclinical to Phase 3 preparation; also served as the global lead of the AstraZeneca/Medimmune breast cancer tumour strategy team

2011 – 2014

作为澳门在线赌城娱乐肿瘤创新药物部门的首席科学家，他的职责越来越大，包括建立一个全球, 跨职能乳腺疾病领域团队制定和执行乳腺癌和女性癌症策略. During these years, 也曾担任2期资产的临床前领导，为乳腺临床试验建立科学假设和设计策略, gastric, colorectal, renal, among others.

2009 – 2011

曾担任澳门在线赌城娱乐肿瘤科的转化科学策略师，以及发现EGFR+肺癌靶向治疗的团队的早期项目负责人

 Featured publications

A randomized, 比较新型口服SERD AZD9496与氟维司汀对ER+ HER2-原发性乳腺癌患者疗效的机会之窗研究.

Robertson JF, Evans A, Henschen S, Kirwan CC, Jahan A, Kenny LM, Dixon JM, Schmid P, Kothari A, Mohamed O, Fasching PA, Cheung KL, Wuerstlein R, Carroll D, Klinowska T, Lindemann JPO, MacDonald A, Mather R, Maudsley R, Moschetta M, Nikolaou M, Roudier MP, Sarvotham T, Schiavon G, Zhou D, Zhou L, Harbeck N. Clinical Cancer Research 2020. Publication link.

 

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W. Cancer Discovery 2014. Publication link.

用新一代mTOR抑制剂克服mTOR耐药突变.

Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, Barratt DG, Cosulich S, Klinowska T, Rosen N, Shokat KM. Nature. 2016 Jun 9;534. Publication link. 

循环生物标志物和转移性乳腺癌对内分泌治疗的耐药性：AZD9496口服SERD I期试验的相关结果.

Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton E, Patel M, Armstrong A, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird R, Hayes DF. Clin Cancer Res. 2018 Dec 1 24 (23), 5860-5872. Publication link.

联合抑制PI3Kβ和mTOR抑制pten缺失肿瘤的生长.

Lynch JT, Polanska UM, Hancox U, Delpuech O, Maynard J, Trigwell C, Eberlein C, Lenaghan C, Polanski R, Avivar-Valderas A, Cumberbatch M, Klinowska T, Critchlow SE, Cruzalegui F, Barry ST. Mol Cancer Ther. 2018 Nov 17 (11), 2309-2319. Publication link.

新型口服选择性雌激素受体降降剂AZD9496治疗ER +/HER2 -晚期乳腺癌的首次人体研究.

Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, Hoch M, Klinowska T, Lindemann JPO, Morgan SR, Schiavon G, Weir HM, Im SA. Clin Cancer Res. 2018 Aug 1, 24 (15), 3510-3518. Publication link. 

在一系列雌激素受体降解物中建立桥梁：复分解在药物化学中的应用.

Scott JS, Breed J, Carbajo RJ, Davey PR, Greenwood R, Huynh HK, Klinowska T, Morrow CJ, Moss TA, Polanski R, Nissink JWM, Varnes J, Yang B. ACS Med Chem Lett. 2019 10(10):1492-1497. Publication link.

HO-1驱动自噬作为抵抗HER-2靶向治疗的机制.

Tracey N, Creedon H, Kemp AJ, Culley J, Muir M, Klinowska T, Brunton VG. Breast Cancer Res Treat. 2019. Publication link. 

Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation.

Hennessy EJ, Chuaqui C, Ashton S, Colclough N, Cross DA, Debreczeni JÉ， Eberlein C, Gingipalli L， Klinowska TC, Orme JP, Sha L, Wu X. ACS Med Chem Lett. 2016 Mar 21;7(5):514-9. Publication link.

AZD2014, an Inhibitor of mTORC1 and mTORC2, 间歇或连续用药对雌激素受体阳性乳腺癌是否有效.

Guichard SM, Curwen J, Bihani T， D'Cruz CM, Yates JW, Grondine M, Howard Z, Davies BR, Bigley G， Klinowska T， Pike KG, Pass M, Chresta CM, Polanska UM, McEwen R, Delpuech O, Green S, Cosulich SC. Mol Cancer Ther. 2015 Nov;14(11):2508-18. Publication link.